Immuron initiated with a Buy at Litchfield Hills

Litchfield Hills analyst Sally Yanchus initiated coverage of Immuron with a Buy rating and $5 price target. Immuron is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases, the analyst tells investors in a research note. The firm says the company’s platform technology enables the development of medicines across a large range of infectious diseases. It believes Immuron shares “appear to be priced significantly below absolute and comparative metrics.”